Targeting of AML1-ETO in t(8;21) leukemia by oridonin generates a tumor suppressor-like protein. by Zhen, Tao et al.
Zhe n,  Tao,  Wu,  Chu a n-Fe n g,  Liu,  Ping,  Wu,  H ai-Yan,  Zhou,  
Gu a n g-Biao,  Lu,  Ying,  Liu,  Jian-Xiang,  Lian g,  Yang,  Li,  Keqin  
Kat hy, Wang,  Yue-Ying,  Xie,  Yin-Yin,  H e,  Miao-Miao,  C ao,  H u a n g-
Ming,  Zh a n g,  Wei-N a,  Ch e n,  Li-Min,  Pe t ri e,  Kevin,  Ch e n,  S ai-
Jua n  a n d  Ch e n,  Zh u  (2012)  Targ e tin g  of  AML1-ETO  in  t(8;21)  
leuk e mia  by  o ridonin  g e n e r a t e s  a  t u m o r  s u p p r e s so r-like  p ro t ein.  
Scie nc e  t r a n sl a tion al  m e dicine,  4  (127).  1 2 7 r a 3 8.  ISS N  1 9 4 6-
6 2 4 2  
Downloa d e d  fro m: h t t p://su r e . s u n d e rl a n d. ac.uk/id/e p rin t /12 4 3 5/
U s a g e  g u i d e l i n e s
Ple a s e  r ef e r  to  t h e  u s a g e  g uid elines  a t  
h t t p://su r e . s u n d e rl a n d. ac.uk/policies.h t ml  o r  al t e r n a tively  con t ac t  
s u r e@s u n d e rl a n d. ac.uk.
 
 1 
Targeting of AML1-ETO in t(8;21) leukemia by oridonin generates a tumor suppressor-like protein 
Running title: Oridonin targets AML-ETO and inhibits LIC activity 
Tao Zhen1*, Chuan-Feng Wu1, 2*, Ping Liu1*, Hai-Yan Wu2*, Guang-Biao Zhou3*, Ying Lu1, Jian-Xiang Liu1, 
Yang Liang1, Keqin Kathy Li1, Yue-Ying Wang1, Yin-Yin Xie1, Miao-Miao He1, Huang-Ming Cao1, Wei-Na 
Zhang1, Li-min Chen1, 4, Kevin Petrie5, Sai-Juan Chen1, 2, 5#, Zhu Chen1, 2, 5# 
1State Key Laboratory of Medical Genomics, Institute of Health Sciences, Shanghai Institutes for 
Biological Sciences, Chinese Academy of Sciences (CAS) & Shanghai Jiao Tong University School of 
Medicine (SJTUSM) and Shanghai Institute of Hematology, Rui-Jin Hospital, 200025, Shanghai, China; 
2Shanghai Center for Systems Biomedicine, SJTU, 800 Dong Chuan Road, 200240, Shanghai, China; 
3Laboratory of Molecular Carcinogenesis and Targeted Therapy for Cancer, State Key Laboratory of 
Biomembrane and Membrane Biotechnology, Institute of Zoology, CAS, 100101, Beijing, China; 4Drug 
Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia 
Medica, CAS, 201203, Shanghai, China; 5Samuel Waxman Cancer Research Foundation Joint 
Translational Research Center, Shanghai Institute of Hematology, Rui-Jin Hospital, SJTUSM, 200025, 
Shanghai, China. 
*These authors contributed equally to this work. 
#To whom correspondence should be addressed. E-mail: zchen@stn.sh.cn or sjchen@stn.sh.cn. 
 
This is the author’s version of the work. It is posted here by permission of the AAAS for personal use, not 
for redistribution. The definitive version was published in Science Translational Medicine on 28 Mar 






Nearly 60% of acute myeloid leukemia (AML) patients with the t(8;21)(q22;q22) translocation fail to 
achieve long-term disease-free survival. Our previous studies demonstrated that oridonin selectively 
induces apoptosis of t(8;21) leukemia cells and causes cleavage of AML-ETO oncoprotein resulting from 
t(8;21), but the underlying mechanisms remain unclear. Here, we show that oridonin interacts with 
glutathione (GSH) and thioredoxin/thioredoxin reductase (Trx/TrxR) to increase intracellular reactive 
oxygen species (ROS), which in turn activates caspase-3 in t(8;21) cells. Moreover, oridonin binds AML1-
ETO, directing the enzymatic cleavage at D188 via caspase-3 to generate a truncated AML1-ETO 
(ΔAML1-ETO), and preventing the protein from further proteolysis. ΔAML1-ETO interacts with AML1-
ETO and interferes with the trans-regulatory functions of remaining AML1-ETO oncoprotein, thus acting 
as a tumor suppressor that mediates the anti-leukemia effect of oridonin. Furthermore, oridonin inhibits 
the activity of c-Kit+ leukemia-initiating cells (LICs). Therefore, oridonin is a potential lead compound for 




Acute myeloid leukemia (AML) is the most common malignant myeloid disorder in adults and a 
heterogeneous clonal disorder of hematopoietic progenitor cells through the acquisition of 
chromosomal rearrangements and multiple gene mutations. The t(8;21)(q22;q22) translocation is the 
most frequent chromosomal rearrangement in AML (12–20%), especially in French-American-British 
(FAB) subtype M2 (AML-M2, 40–50%) (1). The resultant AML1-ETO chimeric protein comprises the N-
terminal 177 amino acids (a.a.) of AML1 (known as RUNX1, CBFa2 or PEBP2ab) and almost the entire 
protein sequence of ETO (also known as MTG8/RUNX1T1). AML1-ETO retains the DNA-binding specificity 
of AML1 and the capacity to recruit ETO-associated regulators, which promotes the self-renewal of 
hematopoietic stem/progenitor cells (1). These combined functions immortalize hematopoietic 
progenitors (2, 3) and induce a myeloproliferative disorder in mice (4). Additional mutations cooperate 
with this critical leukemogenic role of AML1-ETO, resulting in full-blown disease (2, 5, 6). An isoform of 
AML1-ETO with an alternatively spliced exon (exon 9a) of ETO (AML1-ETO9a) can induce leukemia in 
mice (7). Therefore agents that target AML1-ETO could be useful in treating t(8;21) AML (8, 9). 
The principal front-line treatment for AML-ETO positive AML consists of cytosine arabinoside (Ara-C) 
and anthracycline-based chemotherapy (10); however, these therapies result in a median survival of less 
than 2 years and a 5-year overall survival (OS) of no more than 40% (11, 12). In China, 
homoharringtonine has also been added as chemotherapy (13). Notably, the overall response of these 
therapies seems less favorable in East Asian countries with a 5-year OS of 10-40% (14-16). In our 
previous work, oridonin, a diterpenoid isolated from the medicinal herb Isodon rubescens, was 
identified to have relatively selective effect against t(8;21) leukemia cells. In t(8;21) cell lines, oridonin 
triggered caspase-3-dependent cleavage of AML1-ETO at D188, generating a 70 kDa fragment (ΔAML1-
ETO). AML1-ETO-expressing U937 cells also generated ΔAML1-ETO upon oridonin treatment and were 
more sensitive to the apoptotic effect of the compound than parental cells (8).  
In this study, we undertake to identify the proteins targeted and modified by oridonin and address the 
biological functions of ΔAML1-ETO. We also investigate the possible effects of oridonin on leukemia-





Oridonin induces caspase-3 activation and AML1-ETO cleavage through increasing intracellular ROS 
As previously reported (8), oridonin triggered caspase-3 activation as shown by the generation of the 
cleaved caspase-3 and AML1-ETO cleavage with generation of C-terminal truncated protein (ΔAML1-ETO) 
in Kasumi-1 cells (Fig. 1, A and B), while no appearance of N-terminal band was noted using specific 
antibody (fig. S1A). The PML-RARα oncoprotein in an acute promyelocytic leukemia (APL) cell line and 
the BCR-ABL oncoprotein in a chronic myeloid leukemia cell line were resistant to oridonin over 24 hrs of 
treatment (fig. S1B). Expression of ∆AML1-ETO enhanced sensitivity of Kasumi-1 cells to oridonin (fig. S2), 
indicating the selective effect of oridonin on AML1-ETO leukemia cells may be partly mediated by the 
generation of  AML1-ETO. 
We then explored intracellular reactive oxygen species (ROS), essential signals in initiating apoptosis 
and caspase-3 activation (17), under oridonin treatment. In Kasumi-1 cells, intracellular ROS was 
augmented as early as 0.5 hr upon effect of oridonin (Fig. 1C), whereas pre-treatment with ROS 
scavenger N-Acetyl Cysteine (NAC) not only decreased oridonin-induced ROS and apoptosis (fig. S3), but 
also inhibited caspase-3 activation and ∆AML1-ETO production (Fig. 1D). Oridonin also increased ROS 
and generated ΔAML1-ETO in SKNO-1 cells, another t(8;21) cell line, where these effects were also 
blocked by NAC (fig. S4).  
We further examined the mechanisms by which ROS level was increased. Intracellular glutathione 
(GSH), the major molecule in maintaining cellular redox balance, was decreased after oridonin treatment 
in a time-dependent manner (Fig. 1E). Based on the chemical properties of oridonin, it was assumed that 
the compound could react with sulfhydryl (-SH) groups (fig. S5A) and in vitro system using dithio-bis-
nitrobenzoic acid (DTNB) demonstrated an interaction between oridonin and GSH (fig. S5B). It is known 
that the thioredoxin system, composed of thioredoxin reductase (TrxR), thioredoxin (Trx) and NADPH, is 
the major disulfide reducing enzyme system in all cells responsible for maintaining the redox 
homeostasis (18). Since both TrxR and Trx contain cysteines and/or selenocysteines in their active sites 
(19), we examined whether oridonin could interact with them and affect their activities. Indeed, TrxR 
and Trx activities were suppressed by oridonin in Kasumi-1 cells (Fig. 1F). To examine a possible 
interaction between oridonin and TrxR/Trx, a biotin-labeled oridonin (biotin-oridonin) with similar effect 
on ROS induction and ∆AML1-ETO generation was made (fig. S6). Streptavidin agarose affinity assay 
showed that biotin-oridonin could bind TrxR and Trx in Kasumi-1 cells, and unlabeled oridonin competed 
with these interactions (Fig. 1G). The direct binding of oridonin (molecular weight (MW): 364.43) to Trx 
was also demonstrated by matrix-assisted laser desorption/ionization–time-of-flight (MALDI-TOF) mass 
spectrometry (MS) (fig. S7). Thus, induction of cellular ROS by oridonin primarily results from both 
intracellular GSH depletion and TrxR/Trx activity inhibition. 
 
Oridonin binds AML1-ETO to mediate a caspase-3-dependent cleavage at D188 and stabilizes ∆AML1-
ETO 
As reported (8), oridonin triggered caspase-3 dependent cleavage of AML1-ETO with generation of 
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∆AML1-ETO, while doxorubicin, arsenic trioxide and MG132 could not do so though they were able to 
activate caspase-3 (fig. S8), supporting a selective effect of oridonin. Previous studies showed that 
caspase-3 cut AML1-ETO at D188 and D368, and D188V mutation almost abolished the generation of 
∆AML1-ETO under oridonin (Fig. 1B and fig. S9A) (8, 20). Since mutation of D368 (D368A) enhanced the 
generation of ∆AML1-ETO (Fig. 1B and fig. S9B), we hypothesized that oridonin might exert a protective 
role on D368 so that ∆AML1-ETO cleavage could be prevented. 
In an in vitro assay, when purified AML1-ETO was pre-incubated with oridonin, the intensity of 
∆AML1-ETO was considerably increased when caspase-3 was added. Pre-incubation of ∆AML1-ETO with 
oridonin also protected this truncated protein from further attack by caspase-3 (Fig. 2A). Because biotin-
oridonin bound to AML1-ETO/∆AML1-ETO in transfected 293T cells and endogenous AML1-ETO in 
Kasumi-1 cells (Fig. 2B), we assumed that the binding might occur at cysteine residues which contain -SH 
groups. Potential binding sites on distinct domains of AML1-ETO were mapped using MALDI-TOF MS. No 
binding was observed on RHD and NHR3 (fig. S10), whereas NHR1 (also named as TAFH), NHR2 and ZnF 
were capable of oridonin binding (Fig. 1B and Fig. 2, C, D and E). Our interest was then focused on the 
three cysteines (C266, C347 and C416) around D368 at NHR1 which might be important for the 
protective effect of oridonin. Amino acid substitutions were made on these 3 positions and it was 
observed that in the absence of oridonin ∆AML1-ETO with C347A was slightly more resistant to the 
action of caspase-3 than C266A or C416A mutants (Fig. 2F), presumably due to a conformation change of 
AML1-ETO caused by C347A. Notably, unlike C266A and C416A mutants, ∆AML1-ETO with C347A was 
not protected from caspase-3 cleavage in the presence oridonin (Fig. 2F), suggesting that C347 should be 
the critical site for oridonin binding and this binding might also lead to conformational change of AML1-
ETO which might mask D368 from caspase-3 recognition or affect caspase-3 and NHR1 interaction (fig. 
S11). These results indicate that oridonin mediates caspase-3 action selectively to D188, instead of D368, 
and thus stabilizes ∆AML1-ETO. 
 
∆AML1-ETO antagonizes oncogenic activity of AML1-ETO  
Since ∆AML1-ETO persists in t(8;21) cells up to five days after treatment with oridonin (fig. S12) and 
retains the NHR2 domain forming interface with other proteins, we examined its biological functions in 
the context of protein-protein interaction. Co-immunoprecipitation (Co-IP) from transfected cells 
confirmed the interaction between AML1-ETO and ∆AML1-ETO (Fig. 3A (a and b)). Using confocal 
microscopy, when plasmids expressing AML1-ETO-EGFP and ∆AML1-ETO-DsRed2 were transiently co-
expressed in Hela cells, co-localization signal was visible and ∆AML1-ETO shifted the pattern of AML1-
ETO from micropunctate to larger speckles (Fig. 3B). Similarly, oridonin could induce a weak generation 
of ∆AML1-ETO9a in bone marrow (BM) cells of AML1-ETO9a leukemia mice (fig. S13A). ∆AML1-ETO also 
interacted and co-localized with AML1-ETO9a (fig. S13, B and C). To study the effect of ∆AML1-ETO on 
AML1-ETO transcription complex, extracts from 293T cells expressing AML1-ETO and/or ∆AML1-ETO 
were analyzed by size exclusion chromatography (SEC). As shown in Fig. 3C, AML1-ETO complexes 
showed MWs above 669 KDa (21) while ∆AML1-ETO complexes displayed lower MWs. Co-expression of 
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AML1-ETO and ∆AML1-ETO shifted the migration of AML1-ETO to lower MW species between 669 KDa 
and 440 KDa. These data suggest that ∆AML1-ETO may disrupt AML1-ETO complexes via acting on 
partner proteins. 
We subsequently examined DNA binding properties of AML1-ETO complexes by using electrophoretic 
mobility shift assay (EMSA). The binding of AML1-ETO to a consensus AML1 DNA recognition sequence 
from RUNX3 (an AML1 target gene) promoter was diminished by ∆AML1-ETO in a dose-dependent 
manner (Fig. 4A, line 4-8). ∆AML1-ETO also antagonized AML1-ETO-mediated repression of a luciferase 
reporter containing RUNX3 promoter (fig. S14). Moreover, chromatin immunoprecipitation-quantitative 
PCR (ChIP-qPCR) analysis revealed that after treatment of Kasumi-1 cells with oridonin for 24 hrs, the 
association of AML1-ETO with promoters of known targets including UBQLN1, CCPG1 and IL-6R was 
diminished (Fig. 4B) and the suppression effect of AML1-ETO on these genes was relieved (Fig. 4C). Thus, 
∆AML1-ETO antagonizes the DNA binding of AML1-ETO and accordingly abrogates its trans-regulatory 
activities. 
At the cellular level, co-expression of ∆AML1-ETO with AML1-ETO (Fig. 4D) inhibited the increased cell 
proliferation and clonogenic ability driven by AML1-ETO in NIH3T3 cells (Fig. 4, E and F). Moreover, nude 
mice inoculated with AML1-ETO-expressing NIH3T3 cells developed tumors, whereas tumor-inducing 
ability of cells co-expressing ∆AML1-ETO and AML1-ETO was largely compromised (Fig. 4G). We also 
tested the effect of ∆AML1-ETO on murine primary BM cells. As previously reported (22), AML1-ETO 
induced in vitro clonogenic activity of murine BM cells in serial replating assay (Fig. 4H). Notably, ∆AML1-
ETO inhibited the clonogenic potential driven by AML1-ETO (Fig 4H). 
It has been well established that NHR2 mediates the oligomerization of AML1-ETO. Here we showed 
NHR2 serves as a major surface of AML1-ETO/∆AML1-ETO interaction (Fig. 3A(c)). ∆AML1-ETO with 
deletion of NHR2 lost some of its activities at molecular, cellular and organism levels (Fig. 4, A, D and G).  
 
Oridonin inhibits activity of LICs in vitro and in vivo 
Given that ∆AML1-ETO affected the colony-forming ability of AML1-ETO bearing cells, it is reasonable to 
presume that oridonin may have an effect on LICs. We therefore set out to identify a subset of cells from 
BM of AML1-ETO9a leukemia mice (8) with the strongest potential to initiate leukemia. As LICs were 
usually primitive cells, we chose cell surface markers characteristic of normal hematopoietic stem cell 
(Lin-/Sca-1+/c-Kit+) (23, 24) in phenotype analysis in an attempt to enrich LICs. BM cells were harvested 
independently from several diseased mice and were analyzed by flow cytometry. Almost all GFP+ 
leukemia cells were Lin- (99%) and Sca-1- (99.4%) (Fig. 5, A(a) and B), and these cells could be divided 
into two subsets: Sca-1-/c-Kit- and Sca-1-/c-Kit+ (Fig. 5, A(b) and B). To test which subpopulation 
represents LICs in this animal model, the two subpopulations were sorted out and analyzed in vitro or 
injected into mice (2,000 cells/mouse). Greater colony-forming capacity of GFP+/Lin-/Sca-1-/c-Kit+ 
(group A) cells than that of GFP+/Lin-/Sca-1-/c-Kit- (group B) cells was observed (Fig. 5C), and mice 
receiving group A cells had a shorter survival compared with those receiving group B cells (Fig. 5D, 
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p<0.001). Leukemia-initiating analysis showed that the LIC frequency of group A (1/167) was higher than 
that of group B (1/6,159) (table S1). Hence, the group A subpopulation, with a phenotype different from 
the normal hematopoietic cells, may be representative of LICs in AML1-ETO9a leukemia mice.  
We then tested in vitro and in vivo modulatory activities of oridonin on LICs. The number of colonies 
formed by group A cells in culture condition was significantly decreased under oridonin (Fig. 5E). In this 
work, an oridonin formulation suitable for in vivo administration was used in animal treatment and a 
pharmacokinetics analysis of this formulation in rat showed a plasma Cmax of 4.01 μM of oridonin at a 
dose of 2 mg/kg/day (half maximal inhibitory concentration (IC50) for AML1-ETO9a cells: ~2.5 µM). After 
AML1-ETO9a mice were treated with the formulation at 20 mg/kg/day (equivalent to previously 
reported oridonin preparation at 7.5 mg/kg/day (8) in prolonging survival of the mouse model) for three 
weeks, Western blot showed decreased expression of AML1-ETO9a in spleen cells (fig. S15A), and the 
colony formation ability of BM group A cells was suppressed (Fig. 5E) though the percentage of group A 
population in total BM cells was not statistically lowered as compared to controls (fig. S15B). Importantly, 
after 1,000 group A cells from donor animals thus treated were intravenously injected into recipients and 
compared to donor animals without oridonin formulation therapy, mice receiving cells from vehicle-
treated donors died of disease significantly faster (median survival time (MST): 83.5 days) than those 
receiving cells from oridonin-treated donors (112.5 days,  p=0.0005) (Fig. 5F). Of note, the MST of mice 
receiving 1,000 group A cells from donors treated with oridonin formulation in combination with all-
trans retinoic acid (ATRA) and granulocyte colony-stimulating factor (G-CSF), two differentiation inducers 
in a sequential manner was significantly increased (168 days, P<0.0001 or p<0.05 as compared to 
vehicle- or oridonin-treated groups, respectively) (Fig. 5F). A synergistic effect of oridonin/ATRA/G-CSF 
combination was also confirmed in mice inoculated with bulk leukemia cells, in that oridonin alone, 
moderately prolonged the survival (MST from 28 days to 31 days, P<0.01) while ATRA/G-CSF showed no 
improvement (p=0.3057); however, oridonin/ATRA/G-CSF protocol significantly prolonged the survival 
(MST 45.5 days) as compared to the control and oridonin treatment groups (P<0.0001 in both cases, Fig. 
5G). 
To evaluate the safety of oridonin, normal C57BL/6 mice were treated with 20 mg/kg/day or 40 
mg/kg/day oridonin formulation for 3 weeks. The body weight and blood picture were followed-up and 
no obvious adverse effects were observed (fig. S16). 
 
DISCUSSION 
Previous study demonstrated that oridonin selectively targeted AML1-ETO leukemia cells and triggered 
caspase-3-dependent cleavage of AML1-ETO at D188 with generation of ΔAML1-ETO. However, the 
cellular targets of oridonin, the precise mechanism with which oridonin generates ΔAML1-ETO and the 
possible function of ΔAML1-ETO remained unknown. In the present work, we show that oridonin directly 
binds to GSH and targets the active sites of TrxR and Trx to inhibit their activities. These effects result in a 
rapid increase of ROS, which in turn induces apoptosis and caspase-3 activation of t(8;21) leukemia cells. 
Different from other caspase-3 activating compounds investigated here, oridonin is able to induce 
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generation of ∆AML1-ETO through directly binding to AML1-ETO at C347, the nearest cysteine residue to 
the caspase-3 cleavage site D368. A possible consequence of this binding can be a configurational 
change of AML1-ETO vis-à-vis the effect of caspase-3 to D368, preventing the fusion protein from 
cleavage at this site and directing action of caspase-3 mainly to D188. Oridonin induced-∆AML1-ETO 
fragment can interact with AML1-ETO through the NHR2 domain and act as a tumor suppressor by 
means of interfering with the activity of parental AML1-ETO. Moreover, we find that oridonin inhibits 
activity of LICs in AML1-ETO9a leukemia mouse with a characteristic immunophenotype of Lin-/Sca-1-/c-
Kit+, and thereby improves the survival of leukemia mice. A  synergistic effect among oridonin and the 
differentiation inducers ATRA and G-CSF has been demonstrated in that the combination therapy exerts 
statistically more significant effect than oridonin monotherapy in terms of inhibition of the activity of 
Lin-/Sca-1-/c-Kit+ LICs and prolongation of the survival of leukemia mice. Proposed working mechanisms 
of oridonin against t(8;21) AML are summarized in Fig. 6. 
Oridonin has been shown to have myriad of effects on tumor cells, including increase of ROS (25, 26), 
inhibition of NF- B activity, histone hyperacetylation, regulation of cell cycle through p16, p21 and p27, 
c-myc, as well as modulation of MAPK and p53 signaling pathways in solid tumors (27, 28). Here, we 
provide evidence that oridonin induces apoptosis and caspase-3 activation of t(8;21) leukemia cells 
mostly by inducing accumulation of ROS and find the molecular targets of oridonin in rapid increasing of 
ROS.  
Previous work showed that leukemia cells expressing AML1-ETO with D188V mutation were less 
sensitive to oridonin than those expressing wild-type oncoprotein (8). We find in this work that ∆AML1-
ETO acts as a tumor suppressor of AML1-ETO, in support of the notion that ∆AML1-ETO may play a role 
in the anti-leukemia effect and contribute to the selective action of oridonin. It was previously shown 
that a fusion peptide NC128 containing the intact NHR2 domain disrupted the stability of the AML1-ETO 
complexes, restored transcription of certain AML1-ETO target genes, and reverted the differentiation 
block induced by AML1-ETO in myeloid cells (29). A design of small compounds that can interfere with 
NHR2 domain interaction could be a good strategy, but the high stability of AML1-ETO tetramer is a big 
challenge. Since oridonin induces cleavage of AML1-ETO to generate an endogenous fragment that 
effectively disrupts AML1-ETO oligomerization, it may be an ideal alternative for targeting AML1-ETO. 
The remarkable success of selective differentiation/apoptosis induction therapy in APL (30) suggests 
that targeting leukemia-associated oncoprotein(s) is of crucial importance. Indeed, the compound can 
inhibit, under both in vitro and in vivo conditions, leukemia-initiating ability of BM LICs from the AML1-
ETO9a leukemia mice. It is worth mentioning that oridonin improves survival of, but does not cure, AML-
ETO9a leukemia mice. We showed previously that combination of oridonin and Ara-C had a superior 
effect than either agent alone (8). Here, oridonin/ATRA/G-CSF combination not only significantly impairs 
the activity of LICs but also substantially improves the survival of leukemia mice. These results suggest 
that oridonin is a potential compound for molecular target-based therapy of t(8;21) leukemia and a 
phase 0 trial is currently being performed in the Shanghai Institute of Hematology. Nevertheless, the 
pathogenesis of this AML subtype is extremely complex and additional targets such as c-KIT mutations 




MATERIALS AND METHODS 
Cell Culture, reagents and plasmids 
Cells were cultured using standard protocols. For information about reagents and plasmids, see 
Supplementary Material for details.  
Western blot analysis, immunoprecipitation (IP), Co-IP, immunofluorescence and EMSA 
Western blot, IP, Co-IP and immunofluorescence and EMSA assays were performed using standard 
protocols and antibodies indicated. See Supplementary Material for details. 
Assays for ROS production, TrxR and Trx activities, in vitro proteolysis of AML1-ETO protein and SEC  
ROS production determination was performed as previously described (31). TrxR and Trx activities were 
performed with an endpoint insulin assay (32). In vitro proteolysis of AML1-ETO protein (20) and SEC 
assay (21) were performed as described. See Supplementary Material for details.  
MALDI-TOF MS assay 
His-tagged RHD, NHR1, NHR2, NHR3 and ZnF protein domains (Fig. 1B) were expressed in bacteria BL21 
(DE3) and purified by affinity chromatography on Ni-NTA-Agarose (Qiagen). Recombinant purified 
proteins or Trx were incubated with oridoinin (recombinant protein:oridonin=1:1) for 1 hr at room 
temperature. The MWs of proteins and adducts were recorded with MALDI-TOF MS (Shanghai Applied 
Protein Technology Co.Ltd.). 
Streptavidin agarose affinity assay 
293T cells transiently expressing Flag-AML1-ETO or Flag-∆AML1-ETO and Kasumi-1 cells were treated 
with 200 μM biotin-oridonin for 1 hr and lysed with 8 M urea buffer. Cell lysates were incubated with 
streptavidin agarose beads overnight at 4 ℃. After washing with 6 M urea buffer, streptavidin agarose 
beads were resuspended in SDS-PAGE loading buffer and analyzed by Western blot. For oridonin 
blocking, cells were pretreated with 100 μM oridonin for 4 hrs, followed by 200 μM biotin-oridonin 
treatment for 1 hr.  
Proliferation, transformation and in vivo tumor formation assay of NIH3T3 cells 
Bosc23 cells were transfected with MigR1-X (X: AML1-ETO-IRES-GFP, GFP, ΔAML1-ETO-IRES-YFP, ΔAML1-
ETO(ΔNHR2)-IRES-YFP, YFP) plasmids and Ecopac plasmids. Viral supernatants were collected to infect 
NIH3T3 cells and the GFP and YFP double positive cells were sorted out with MoFlo High-speed Cell 
Sorter (DakoCytomation) for assays of proliferation, transformation and tumor formation. See 
Supplementary Material for details. 
Murine model establishment and drug treatments 
Experiments were carried out according to the NIH Guide for Care and Use of Laboratory Animals. For 
murine model establishment, C57BL/6 mice housed in specific pathogen-free conditions were irradiated 
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and injected with 3×106 leukemia cells as described (7, 8). An oridonin formulation suitable for in vivo 
administration provided by Jiangsu Hengrui Medicine Company was used to treat animals. Three days 
after leukemia cell transplantation, the mice were subjected to treatment protocols as follows: 5% 
glucose (vehicle); oridonin formulation given at 20 mg/kg/day for three weeks (oridonin); vehicle (4 days) 
followed by G-CSF (50 μg/kg/day) and ATRA (10 mg/kg/day) (3 days) for three weeks (G-CSF/ATRA); 
oridonin formulation (4 days) followed by G-CSF+ATRA (3 days) for three weeks (oridonin/ATRA/G-CSF).  
Colony-forming ability and serial replating assay of mice BM cells 
2×104 indicated mouse cells were used for colony-forming assay with MethoCult M3434 (StemCell 
Technologies) according to manufacture’s instruction. Serial replating assay of BM cell was performed as 
previously described (22). 
Statistical analysis 
Results were expressed as means ± SEM, Differences among groups were tested with the Student’s t-test. 
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FIGURES and LEGENDS 
 
Fig. 1. Oridonin induces caspase-3 activation and AML1-ETO cleavage through increasing intracellular 
ROS. (A) Cells were treated with oridonin (ori, 5 μM, same for C-F) and Western blot (WB) was 
performed to check AML1-ETO (AE) status and caspase-3 activation. ∆AE, ∆AML1-ETO; hrs, hours. β-actin 
was used as internal control. (B) Schematic structures of AML1-ETO-related constructs, including 
domains for oridonin binding assays. ↑: caspase-3 cleavage site (D188 and D368 respectively), ▲: 
position of cysteine. (C) Intracellular ROS was measured under oridonin for indicated hrs using DCFH-DA 
(mean ± SEM). (D) Cells were pre-incubated with NAC for 1 hr before oridonin treatment for 12 hrs. 
Caspase-3 activation and generation of ∆AML1-ETO were analyzed by WB. (E) GSH content was 
measured in Kasumi-1 cells treated with oridonin (mean ± SEM) using a total GSH kit (Dojin Laboratories). 
(F) TrxR (a) and Trx (b) activities in Kasumi-1 cells treated with oridonin (mean ± SEM). (G) Streptavidin 
agarose affinity assay was performed to detect oridonin-interacting TrxR and Trx in Kasumi-1 cells. All 





Fig. 2. Oridonin directly binds to AML1-ETO and stabilizes ∆AML1-ETO. (A) Immunoprecipitated Flag-
AML1-ETO (a) or Flag-∆AML1-ETO (b) was incubated with or without 0.2 mM oridonin for 1 hr, washed to 
eliminate oridonin, and then incubated with caspase-3 (0.2 μg) for 1 hr. WB was performed to detect the 
fragments of AML1-ETO or ∆AML1-ETO. (B) Streptavidin agarose affinity assay was performed to detect 
oridonin-interacting AML1-ETO or ∆AML1-ETO in 293T cells transiently expressing Flag-AML1-ETO (a) or 
Flag-∆AML1-ETO (b) and Kasumi-1 cells (c). (C-E) Mass spectrum analysis of NHR1 (C), NHR2 (D) and ZnF 
(E) domains, as illustrated in Fig. 1B, in the absence (a) or presence (b) of oridonin. (F) 
Immunoprecipitated Flag-∆AML1-ETO mutant proteins were incubated with or without 0.2 mM oridonin 





Fig. 3. ∆AML1-ETO interacts with AML1-ETO through NHR2 domain. (A) Co-IP analysis of nuclear 
extracts from transfected 293T cells to check interaction between AML1-ETO and ∆AML1-ETO (a and b), 
and between AML1-ETO and ∆AML1-ETO with deletion of NHR2 [∆AML1-ETO(∆NHR2)] (c). I: 
immunoprecipitate; S: supernatant. (B) Direct immunofluorescence staining in Hela cells transfected 
with indicated plasmids to reveal possible co-localization of AML1-ETO and ∆AML1-ETO. (C) SEC 
examination for apparent molecular weight distribution of AML1-ETO in the presence of ∆AML1-ETO. 




Fig. 4. ∆AML1-ETO antagonizes the activities of AML1-ETO. (A) EMSA assay. AML1-ETO purified from 
293T cells were mixed with different amounts of ∆AML1-ETO, and relative amounts of AML1-ETO and/or 
∆AML1-ETO or ∆AML1-ETO(∆NHR2) used are shown at the bottom. #: shift; ##: supershift with anti-ETO 
antibody. (B) ChIP-qPCR was performed in oridonin (5 µM)-treated Kasumi-1 cells to detect binding of 
AML1-ETO to target gene promoters. BLNK was used as a negative control (mean ± SEM). (C) Semi-
quantitative PCR was performed to detect the mRNA expression of UBQLN1, CCPG1 and IL-6R after 
Kasumi-1 cells were treated with oridonin for 24 hrs. (D-G) NIH3T3 cells were infected with different 
retroviral constructs as indicated. GFP+/YFP+ NIH3T3 cells of each group were isolated. Expression of 
AML1-ETO, ∆AML1-ETO or ∆AML1-ETO(∆NHR2) was confirmed by WB (D). Proliferation ability (E), 
colony-forming capacity (F) and tumorigenicity in nude mice (G) of these cells were examined and data 
represented as mean ± SEM. (H) Serial replating assay was performed in mice BM cells to exam the effect 
of ∆AML1-ETO on AML1/ETO’s clonogenic activity in vitro. Numbers are averaged from two experiments, 




Fig. 5. Oridonin inhibits activity of LICs. (A-B) Flow cytometry assay of BM cells from AML1-ETO9a 
leukemia mice with indicated markers. (A) GFP+/Lin- cells (a) were further analyzed using c-Kit and Sca-1 
markers (b). Data are representative of three mice. (B) Percentages of Lin+, Lin-/Sca-1+, Sca-1-/c-Kit- and 
Sca-1-/c-Kit+ in GFP+ cells. (C) Colony-forming ability of 4×104 GFP+/Lin-/Sca-1-/c-Kit+ and GFP+/Lin-
/Sca-1-/c-Kit- cells. (D) Kaplan-Meier estimates of cumulative survival of mice inoculated with 2,000 
GFP+/Lin-/Sca-1-/c-Kit+ (red) or GFP+/Lin-/Sca-1-/c-Kit- (blue) cells (mean ± SEM). (E) Effect of oridonin 
on colony-forming ability of GFP+/Lin-/Sca-1-/c-Kit+ cells in vitro (Ori 5 M) and in vivo when AML1-ETO9a 
mice were treated with oridonin (Ori) (mean ± SEM). (F-G) AML1-ETO9a mice were treated with different 
protocols: vehicle (black); oridonin (blue); ATRA/G-CSF (brown); oridonin/ATRA/G-CSF (red). (F) Kaplan-
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Meier estimates of cumulative survival of mice inoculated with 1,000 GFP+/Lin-/Sca-1-/c-Kit+ cells from 
BM of different donor groups. (G) Kaplan-Meier estimates of cumulative survival of mice transplanted 
with bulk leukemia cells treated with different protocols. For (B), (C) and (E), all experiments were 
independently performed in triplicates. ***p<0.001, **p<0.01 when compared with vehicle or as 




Fig. 6. A summary diagram outlines the working mechanisms of oridonin in the treatment of AML1-
ETO positive leukemia. Oridonin interacts with GSH and Trx/TrxR to increase ROS, which in turn 
activates caspase-3. Moreover, oridonin binds AML1-ETO, directing the enzymatic cleavage at D188 via 
caspase-3 to generate ΔAML1-ETO, and preventing the protein from further proteolysis. ΔAML1-ETO 
interacts with AML1-ETO and interferes with the trans-regulatory functions of remaining AML1-ETO 
oncoprotein. 
